-
公开(公告)号：US20240360217A1
公开(公告)日：2024-10-31
申请号：US18440582
申请日：2024-02-13
Applicant: Merus N.V.
IPC: C07K16/28
CPC classification number: C07K16/2827 , C07K16/2809 , C07K16/2851 , C07K16/2863 , C07K2317/31 , C07K2317/35 , C07K2317/522 , C07K2317/53 , C07K2317/55
Abstract: The invention relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein the base antibody portion is connected by a linker to the at least one additional binding domain, wherein each binding domain of the base antibody portion and each of the at least one additional binding domains all have a common variable region, and wherein the linker comprises a hinge sequence or a sequence derived from a hinge sequence. The invention also relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein at least one additional binding domain comprises a CH1 region and is connected to the base antibody portion by said linker, linking a variable region of the base antibody portion and the CH1 region, and wherein the multivalent antibody binds to at least three different epitopes.
-
公开(公告)号：US20240262911A1
公开(公告)日：2024-08-08
申请号：US18398935
申请日：2023-12-28
Applicant: Merus N.V.
CPC classification number: C07K16/2809 , A61K2039/505 , C07K2317/31 , C07K2317/53 , C07K2317/565
Abstract: The present disclosure relates to the field of antibodies. In particular it relates to the field of producing therapeutic antibodies. More particularly it relates to anti-CD3 heavy chain variable regions that can pair with multiple different light chain variable regions to form functional CD3 binding domains, and CD3 binding domains and CD3 binding moieties comprising such anti-CD3 heavy chain variable regions.
-
公开(公告)号：US20220348683A1
公开(公告)日：2022-11-03
申请号：US17675431
申请日：2022-02-18
Applicant: Merus N.V.
Inventor： Cecilia Anna Wilhelmina GEUIJEN , Cornelis Adriaan DE KRUIF , Mark THROSBY , Ton LOGTENBERG , Alexander Berthold Hendrik BAKKER
IPC: C07K16/32 , A61K31/185 , A61K31/337 , A61K31/436 , A61K31/4375 , A61K31/4439 , A61K31/519 , A61K39/395 , C07K16/30
Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.
-
公开(公告)号：US20170327860A1
公开(公告)日：2017-11-16
申请号：US15496807
申请日：2017-04-25
Applicant: Merus N.V.
IPC: C12P21/00 , A61K39/395 , A61K39/40 , C07K16/12 , C07K16/46 , C07K16/36 , C07K16/28 , C07K16/26 , C07K16/18 , A61K39/00
CPC classification number: C12P21/005 , A61K39/395 , A61K39/3955 , A61K39/40 , A61K2039/507 , C07K16/12 , C07K16/1278 , C07K16/1282 , C07K16/18 , C07K16/26 , C07K16/28 , C07K16/2809 , C07K16/283 , C07K16/2866 , C07K16/2896 , C07K16/36 , C07K16/468 , C07K2317/14 , C07K2317/31 , C07K2317/526 , C07K2317/56 , C07K2317/94
Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.
-
公开(公告)号：US20240344102A1
公开(公告)日：2024-10-17
申请号：US18431564
申请日：2024-02-02
Applicant: Merus N.V.
IPC: C12P21/00 , A61K39/395 , A61K39/40 , C07K16/12 , C07K16/18 , C07K16/26 , C07K16/28 , C07K16/36 , C07K16/46 , A61K39/00
CPC classification number: C12P21/005 , A61K39/395 , A61K39/3955 , A61K39/40 , C07K16/12 , C07K16/1278 , C07K16/1282 , C07K16/18 , C07K16/26 , C07K16/28 , C07K16/2809 , C07K16/283 , C07K16/2866 , C07K16/2896 , C07K16/36 , C07K16/468 , A61K2039/507 , C07K2317/14 , C07K2317/31 , C07K2317/526 , C07K2317/56 , C07K2317/94
Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.
-
Patent Agency Ranking
公开(公告)号：US20240309115A1
公开(公告)日：2024-09-19
申请号：US18553114
申请日：2022-03-30
Applicant: MERUS N.V.
Inventor： Simon Edward PLYTE , Cornelis Adriaan DE KRUIF
CPC classification number: C07K16/468 , A61P35/00 , C12N15/64 , A61K2039/505 , C07K2317/31 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565
Abstract: The present disclosure relates to a multispecific antibody comprising a binding domain that binds to LAG-3 and a binding domain that binds to PD-L1. Such multispecific antibody has comparable, or equal or higher, potency than a combination of LAG-3 and PD-L1 reference antibodies. Also provided is a method for treating a disease, in particular a disease associated with a suppressed immune system, such as cancer, with a multispecific antibody of the present disclosure. The present disclosure further relates to a vector and cell comprising nucleic acids encoding the heavy chain variable region of the LAG-3 and PD-L1 binding domains.
-
公开(公告)号：US20240034794A1
公开(公告)日：2024-02-01
申请号：US18062871
申请日：2022-12-07
Applicant: Merus N.V.
Inventor： Cecilia Anna Wilhelmina GEUIJEN , Rinse KLOOSTER , Cornelis Adriaan DE KRUIF , Paulus Johannes TACKEN , Mark THROSBY , Ton LOGTENBERG
CPC classification number: C07K16/2818 , A61P35/00 , A61K2039/505 , C07K16/30 , C07K16/468 , C07K16/2827
Abstract: The invention provides means and methods for inhibiting a biological activity of cells. In one embodiment the invention is concerned with a method of inhibiting a biological activity in a first or second cell mediated by the binding of two membrane proteins that are binding partners for each other. The mentioned biological activity is inhibited by providing the cells with an antibody or antibody like molecule that can bind to each of the mentioned binding partners and the binding blocks the binding of the two binding partners thereby inhibiting the mentioned biological activity.
-
公开(公告)号：US20220073649A1
公开(公告)日：2022-03-10
申请号：US17417291
申请日：2019-12-27
Applicant: Merus N.V.
Inventor： Cornelis Adriaan DE KRUIF
Abstract: A binding domain or a multimer or a variant thereof which comprises a variable region encoded by a nucleic acid based on, derived or obtained from an animal phylogenetically distal from a human, which variable region is paired with a human variable region.
-
公开(公告)号：US20200216540A1
公开(公告)日：2020-07-09
申请号：US16628939
申请日：2018-07-06
Applicant: Merus N.V.
Inventor： Cecilia Anna Wilhelmina GEUIJEN , Rinse KLOOSTER , Cornelis Adriaan DE KRUIF , Paulus Johannes TACKEN , Mark THROSBY , Ton LOGTENBERG
IPC: C07K16/28
Abstract: The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3.
-
公开(公告)号：US20240174756A1
公开(公告)日：2024-05-30
申请号：US18446795
申请日：2023-08-09
Applicant: MERUS N.V.
Inventor： Cecilia Anna Wilhelmina GEUIJEN , Robertus Cornelis ROOVERS , Mark THROSBY , Cornelis Adriaan DE KRUIF , Ton LOGTENBERG
CPC classification number: C07K16/2863 , A61P35/00 , C07K16/40 , A61K2039/505
Abstract: The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some aspects, the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some aspects, the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.018 seconds)
